To provide accessible and innovative genetic technologies, products and services for all.
Sansure Biotech Inc., a listed company in China, is a comprehensive provider of integrated diagnosis and treatment solutions, with independent and innovative gene technology at its core. Founded in 2008 by Dr. Lizhong Dai, Sansure began its journey in Changsha and has since established strategic hubs in Beijing and Shanghai, building strong connections both domestically and internationally. Over the years, the company has expanded its global presence further, establishing more than 30 subsidiaries and offices worldwide.
With over 40% of employees dedicated to R&D, Sansure has built a strong foundation of scientific talent that drives continuous innovation. Leveraging this strength, the company has pioneered a series of leading core technologies and developed over 1,000 products, along with more than 2,200 kinds of high-quality testing services, all exceeding domestic and global standards. The innovation capacity is further evidenced by more than 1,400 patents filed and currently in force worldwide, and over 1,800 domestic and international registrations and approvals, including more than 500 CE-marked products. Sansure’s products and solutions are used by over 10,000 benchmark hospitals and laboratories worldwide, serving billions of people across over 160 countries and regions.
Sansure is gradually driving comprehensive upgrades in life sciences, transitioning from disease solutions to smart health management, from top-tier hospitals to primary care facilities, and from B2B to B2C, aiming to cover all populations, all healthcare facilities, and all channels.
Mission and Vision Statement
Sansure continues to fulfill its mission of providing accessible and reliable diagnosis and treatment technologies, products, and services for people around the world, and consistently pursues its vision of creating a new industry ecosystem of co-creation, joint advancement, shared benefits, and mutual success, making life sciences accessible for all. With unwavering determination, Sansure will continue to advance its transformation into a world-class life sciences enterprise.
Innovating Diagnostics for All
In today's rapidly evolving healthcare landscape, biotechnology is a key player in advancing diagnostic capabilities. Biotech companies constantly strive for innovation, seeking to improve the accuracy, accessibility, and affordability of diagnostic tests, ensuring efficient healthcare delivery to populations in need.
The slogan "Innovating Diagnostics for All" embodies Sansure's commitment to promoting accessibility and equity in healthcare. Diagnostic kits aim to bridge the gap between developed and developing regions, urban and rural areas, and diverse socioeconomic backgrounds. By creating cost-effective, user-friendly, and scalable tests, biotech companies remove barriers that impede timely and accurate diagnoses. "For all" represents Sansure's aspiration to ensure that individuals from all walks of life can benefit from their improved diagnostic solutions.
The slogan also encompasses Sansure's dedication to advancing disease detection and prevention strategies. Through prioritized research and development, these companies continuously strive to enhance the accuracy of their kits in identifying pathogens, diagnosing diseases, and safeguarding one's health. Proactive disease detection leads to improved treatment outcomes and reduced healthcare costs. Additionally, innovative diagnostic solutions contribute to public health initiatives, exemplifying a commitment to improving population health and lessening the burden of diseases worldwide.
The term "innovation" reflects the dedication to developing solutions that optimize patients' well-being in the face of health crises. This is exemplified by advanced technologies utilized in diagnostic testing, employing techniques that enhance sensitivity, specificity, and speed.
Milestone
Established Sansure Biotech Inc. Initiated the reagent product line.
Developed world-leading, high-precision Advanced Magnetic Beads Technology.
Launched China’s first world-class, high-precision Hepatitis B Nucleic Acid Diagnostic kit.
Developed world-leading, fast and simple One-tube Fast Release Technology.
Obtained CE marking for international market entry.
Recognized as a National High-Tech Enterprise.
Launched the automated instrument product line.
Introduced nearly 10 new nucleic acid products, including HCV Pro.
Began construction of Sansure Changsha Industrial Base.
Launched the blood screening product line.
Introduced the Magnetic Beads Automated Nucleic Acid Extraction System.
Proposed the “high-precision, simplified, automated, systematized, and portable” strategy.
Established Sanway Clinical Laboratory Co.,Ltd.
Introduced over 30 new products, including for HFMD, TB, and EB.
Inaugurated Sansure Changsha Industrial Base.
Initiated the gene sequencing product line and bio-information platform.
Launched the One-tube Automated Nucleic Acid Extraction System.
Won the Second Prize of the National Science and Technology Progress Award.
Established POCT, liquid chip, and multiplex PCR technology platforms.
Launched the Natch S automated nucleic acid extraction system.
Authorized as the National Genetic Testing Technology and Application Demonstration Center.
Launched the Universal Automated Nucleic Acid Extraction System.
Introduced 10 new products, including HPV and Flu A.
Secured a strategic investment of 500 million yuan (approximately USD 70 million) .
Authorized as a National-Local Joint Engineering Research Center for Genetic Diagnosis of Infectious Diseases and Tumors.
Sanway Clinical Laboratory received ISO 15189 accreditation.
Dr. Dai Lizhong was elected as a deputy to the National People’s Congress.
Established Sansure Biotech (Shanghai) Ltd., accelerating internationalization.
Established Institute of Life Sciences, approved as a National Postdoctoral Research Workstation.
Launched HBV Ultra, HCV Ultra, CT/UU/NG, among others.
Introduced RNA One-Tube Fast Release Technology and Metagenome Sequencing Technology Platform.
The Customer Service Department was awarded “National Worker Pioneer”.
Launched a series of anti-COVID-19 products, including nucleic acid testing kits and POCT solutions.
"Sansure Solution" for SARS-CoV-2 became dominant in many countries.
Listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange.
Acquired GeneMind to enter upstream fields of gene sequencing.
Expanded into animal testing through investment in Geniecare.
Launched 6 RP, SARS-CoV-2/Flu A/B, and iPonatic II.
Established subsidiaries in Indonesia and the UK.
Launched HPV 13+2, AdV, 6 LRP, HIV-1, among others.
HBV Ultra, HCV Ultra, HIV-1 and NAT blood screening kit CE List A marked (first in China, second worldwide).
Inaugurated Sansure Beijing Industrial Base.
Established Sansure Biotech Industrial Fund, L.P.
Launched the immunodiagnostics strategy.
Released new products: Direct-Amplification Drip Tube, iPonatic III, Surelite 8, YnY3030.
Inaugurated Sansure Shanghai Industrial Base.
Launched sansurelink, a digital intelligence system for testing, monitoring and predicting "disease X".
Won first place in the iDASH 2024 Secure Genome Analysis Competition, Track I: Secure Neural Network Evaluation for Protein Sequence Classification.
Acquired Sansure Hygene, entered the biopharmaceutical industry and launched the “Integrated Diagnosis and Treatment” strategy.
Pioneered a seamless healthcare service model linking top-tier hospitals,primary care facilities, and home-based services.
Acquired Hongan, expanding into the hematology field.
